ReviewTherapeutic advances in musculoskeletal disease2018
The role of the JAK/STAT signal pathway in rheumatoid arthritis.
Review in Therapeutic advances in musculoskeletal disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 157 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
157 citing papers in PubMed, 4 syntheses or guidelines pooled it, 282 citations in OpenAlex.
- Real-World Evidence for Baricitinib in the Treatment of Rheumatoid Arthritis in Spain: A Systematic Literature Review.Advances in therapy · 2025Pooled it
- Molecular insights into phytochemicals exhibiting anti-arthritic activity: systematic review : John Di Battista.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Pooled it
- Current jakinibs for the treatment of rheumatoid arthritis: a systematic review.Inflammopharmacology · 2021Pooled it
- Pooled it
- Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.Annals of the rheumatic diseases · 2019Trial
- Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.Clinical pharmacokinetics · 2019Trial
- Integrated network pharmacology and metabolomics reveal the mechanisms of Compound Nanxing Zhitong Plaster in anti-rheumatoid arthritis.Clinical rheumatology · 2026Article
- Reticuline alleviates rheumatoid arthritis by suppressing the JAK/STAT signaling pathway.Clinical rheumatology · 2026Article
- Evaluation of serum antioxidant markers and calcium levels in women with Arthritis.Pakistan journal of medical sciences · 2026Article
- β-Sitosterol-loaded leciplexes attenuate rheumatoid arthritis in rats by modulating JAK2/STAT3, NF-κB, and p38 MAPK signaling pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Effective virtual screening strategy toward JAK3 covalent inhibitors: combining multi‑conformational consensus calculation with covalent docking.Molecular diversity · 2026Article
- Cellular Products with Anti-Inflammatory Properties for the Treatment of Cartilage Lesions.International journal of molecular sciences · 2026Review
- JAK2 and NOTCH2 in gastric cancer - NOTCH2 is an independent prognosticator of poor patient outcome.Virchows Archiv : an international journal of pathology · 2026Article
- Narrative review on the development of multi-target pharmacological agents for the management of rheumatoid arthritis.Inflammopharmacology · 2026Review
- Identification of SDC1 as a Key Regulator and Therapeutic Target in Rheumatoid Arthritis via JAK2-STAT3 Pathway.International journal of rheumatic diseases · 2026Article
- In Silico Functional and Structural Analysis ofGenes · 2026Article
- Therapeutic expansion of JAK inhibitors in Chinese dermatological practice: beyond atopic dermatitis to novel autoimmune frontiers.Frontiers in medicine · 2026Review
- Review
- multiDEGGs: Single or Multiomic Differential Network Analysis for Biomarker Discovery and Feature Engineering for Predictive Modeling.Computational and structural biotechnology journal · 2026Article
- Cytokine-mediated pathophysiology of equine and human joint disease: mechanisms, biomarkers, and therapeutic targets.Frontiers in veterinary science · 2026Review
97 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedCorrigendum.2018
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Proinflammatory cytokine activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signal transduction pathway is a critical event in the pathogenesis and progression of rheumatoid arthritis. Under normal conditions, JAK/STAT signaling reflects the influence of negative regulators of JAK/STAT, exemplified by the suppressor of cytokine signaling and protein inhibitor of activated STAT. However, in rheumatoid arthritis (RA) both of these regulators are dysfunctional. Thus, continuous activation of JAK/STAT signaling in RA synovial joints results in the elevated level of matrix metalloproteinase gene expression, increased frequency of apoptotic chondrocytes and most prominently 'apoptosis resistance' in the inflamed synovial tissue. Tofacitinib, a JAK small molecule inhibitor, with selectivity for JAK2/JAK3 was approved by the United States Food and Drug Administration (US FDA) for the therapy of RA. Importantly, tofacitinib has demonstrated significant clinical efficacy for RA in the post-US FDA-approval surveillance period. Of note, the success of tofacitinib has spurred the development of JAK1, JAK2 and other JAK3-selective small molecule inhibitors, some of which have also entered the clinical setting, whereas other JAK inhibitors are currently being evaluated in RA clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.